Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Treatment for Advanced Tumors: Src Reclaims Center Stage

Open access
Summy, Justin M., Gallick, Gary E. · 2006 · Clinical Cancer Research

Abstract

The non–receptor protein tyrosine, Src, is a 60-kDa protein that is the archetypal member of a nine-gene family, including Src, Yes, Fyn, Lyn, Lck, Hck, Fgr, Blk, and Yrk, that plays a critical role in regulation of proliferation, differentiation, migration, adhesion, invasion, angiogenesis, and immune function (for detailed reviews, see refs. 1–4). All Src family kinases are myristoylated at the NH2 terminus, and several are additionally palmitoylated downstream of the myristoylation site. These fatty acid moieties are required for localization to cellular membranes. Each Src family kinase contains a poorly conserved (“unique”) domain and three conserved Src homology domains: SH2, SH3, and SH1 or protein tyrosine kinase domain. Critical to the regulation of Src is a COOH-terminal tyrosine (Y530) that, when phosphorylated by C-terminal Src kinase (Csk), leads to a more inactive Src conformation, as has been shown by numerous molecular studies and confirmed by crystal structures (5). An autophosphorylation site (Y418) is indicative of, but not entirely diagnostic for, Src activation. Biochemical and structural studies have discerned the general mechanism by which Src activity is regulated (6).A myriad of cellular stimuli, including polypeptide growth factors, hormones, integrin aggregation, stress, cell cycle progression, and undoubtedly others, lead to the phosphorylation of signaling proteins for which the Src SH2 domain has higher affinity than for its own COOH-terminal phosphorylated site. Src thus associates with numerous proteins (depending on the input signal) and assumes an active conformation through phosphatase-mediated dephosphorylation of Y530 and autophosphorylation of Y418. Through its SH2 and SH3 domains, Src further associates with structural and signaling proteins, and the resulting complexes are critical to Src's role in diverse cellular processes, as illustrated in Fig. 1. Specificity of Src signaling stems from the composition of these complexes as well as their duration and subcellular localization and may be additionally influenced by phosphorylation sites on Src mediated by protein kinase C, protein kinase A, cdc2 kinase, and growth factor receptors (7). In turn, Src substrates include signaling enzymes, cytoskeletal proteins, mitotic regulators, etc. (8).Aberrantly high Src activity is seen in diverse cancers (9). Although a number of mechanisms may account for these increases, including increased transcription (10) and perhaps very rare activating mutations (4), activation is likely primarily a consequence of genetic and epigenetic alterations in tumor cells. As examples, overexpression and mutation of growth factor receptors and alterations in integrin regulation and downstream mediators, such as overexpression of focal adhesion kinase, frequently lead to activation of Src and deregulation of one or more of the pathways depicted in Fig. 1. As these epigenetic changes accumulate, Src activity increases during cancer progression, with the highest expression and/or activity of Src observed in metastases (11, 12). Src activity can be predictive of poor prognosis (13). Thus, current expectation is that Src inhibitors will hold the most promise for later stage neoplasms, and clinical trials are focusing on this potential. Src activation is not always confined to late-stage tumors, however, as it occurs in colon polyps of high malignant potential (14) as well as in ulcerative colitis (15) and can promote hyperproliferation in mouse models of skin carcinogenesis (16). Thus, in some malignancies, Src inhibitors may have efficacy in earlier-stage disease.Recent studies using in vitro and in vivo models provide strong support for the use of Src inhibitors for cancer therapy. In models of epithelial cancer, Src activation promotes a more migratory and invasive phenotype, inducing morphologic and biochemical changes more commonly associated with fibroblasts and cells of mesenchymal origin (17), often termed epidermal to mesenchymal–like transition. This phenotype is associated with increased formation of integrin adhesion structures and decreased E-cadherin–mediated cell-cell contacts (18). Intact Src SH3 and SH2 domains are essential for formation of the focal adhesion–like integrin adhesion complexes (19), and Src catalytic activity is important for the dynamic modulation (including elongation and retraction) that occurs at these sites (20). A current area of intense investigation is proteomic analysis of whether specific alterations (such as phosphorylation) in proteins in these complexes will be predictive markers for patient response to Src inhibitors.Another key role of Src that may be exploited therapeutically is its regulation of critical angiogenic factors that promote tumor progression. Src activation is required for hypoxia-mediated expression of vascular endothelial growth factor (VEGF; ref. 21), and in mouse models using colon cancer cells, inhibition of Src inhibits VEGF expression

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-2692

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 225

Metadata

Authors
Summy, J. M., & Gallick, G. E.
Venue
Clinical Cancer Research
Published
2006-03-01
Volume
12
Issue
5
Pages
1398-1401
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2136929338
Cited by
225
References
9
FWCI
15.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment for Advanced Tumors: Src Reclaims Center Stage. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2692
The paper
Summy, J. M., & Gallick, G. E. (2006). Treatment for Advanced Tumors: Src Reclaims Center Stage. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2692

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.